Next 10 |
home / stock / crl / crl articles
Charles River Laboratories International Inc (NYSE:CRL) reported fourth-quarter 2023 revenue of $1.01 billion, a decrease of 7.9% Y/Y, beating...
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and...
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday. Shares of Charles River Laboratories International, I...
Disclosed in a recent SEC filing on January 31, Foster, Chairman at Charles River (NYSE:CRL), made a noteworthy transaction involving the exercise ...
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Dollar General Corporation Johnson Fistel, LLP is investigating potential claims on behalf of Doll...
SAN DIEGO, Nov. 17, 2023 (GLOBE NEWSWIRE) -- FedEx Corporation (NYSE:FDX) Johnson Fistel, LLP is investigating potential claims on behalf of Fe...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make...
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating ...
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. Near Intelligence, Inc. (NASDAQ: NIR) g...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
ESG progress includes $200M investment in alternative testing methods; achievement of 92% renewable energy usage worldwide Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report , which includes progress an...
Collaboration provides phase-appropriate plasmid DNA to support the development of engineered stem cells for cancer therapy Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicin...
Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As pa...